Slides
Page 1
CORPORATE OVERVIEW June 2025
Page 2
2 © 2025 Spyre Therapeutics, Inc. All rights reserved. Disclosures The information contained in this presentation has been prepared by Spyre Therapeutics, Inc. and its affiliates (“Spyre” or the “Company”) and contains information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as third party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; (d) is for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful. Where any opinion or belief is expressed in this presentation, it is based on certain assumptions and limitations and is an expression of present opinion or belief only. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. This document is for informational purposes only and should not be considered a solicitation or recommendation to purchase, sell or hold a security. Forward-Looking Information Certain information set forth in this presentation contains “forward-looking statements” within the meaning of applicable United States securities legislation. Except for statements of historical fact, certain information contained herein constitutes forward- looking statements which include but are not limited to statements regarding: our business strategy, including our ability to develop best-in-class and first-in-class therapeutics for inflammatory bowel disease (IBD), rheumatoid arthritis (RA), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA) and other immune-mediated diseases that meaningfully improve both efficacy and convenience compared to today’s standard of care; the potential consistency of the SPY001, SPY002 and SPY072 Phase 1 trial final data readouts with the interim Phase 1 results; the efficacy, safety profile, dosing regime, convenience, commercial viability and tolerability of SPY001, SPY002, SPY072 and our other product candidates; our plans to advance both SPY002 and SPY072 programs into Phase 2 clinical trials; Spyre’s ongoing and future clinical development activities, including the expected design and timing of the planned platform SKYWAY-RD Phase 2 basket trial, including timing of data readouts, timing of data readout for the ongoing SPY003 Phase 1 trial, timing of each part, cohort and data readouts for the ongoing SKYLINE -UC Phase 2 platform trial, enrollment of clinical trials and number of data readouts expected to be delivered in 2026 and 2027; our ability to provide anticipated readouts ahead of any disclosed bispecific approaches against our targets; the planned induction and maintenance dosing regimen for SPY001 and our other product candidates, including the potential for a Q3M-Q6M dosing profile; the potential therapeutic benefits of our product candidates as monotherapies or in combinations and their extended half-life, including the expected duration of half-life in comparison to competitor products; potential cost savings from the trial designs of our Phase 2 platform trial and Phase 2 basket trial; potential alignment with regulatory authorities and anticipated regulatory submissions; expected timing for regulatory feedback; estimated market sizes, potential growth opportunities, potential value creation and sample transactions; the length of time that the Company believes its existing cash resources will fund its operations, including expectations of cash runway extending into the second half of 2028; expectations regarding our potential therapeutic combinations, including dosing regime, and the potential benefits thereof; and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect. Forward-looking statements can often be identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, ‘believe”, expect”, “intend”, “potential”, “estimate”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions or the negatives thereof. Forward-looking statements are neither historical facts nor assurances of future performance. Forward-looking statements are based on a number of factors and assumptions made by management and considered reasonable at the time such information is provided, and forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements, including uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s interpretation of data and the Company’s planned clinical trials for its product candidates, including the Company’s planned SKYWAY-RD Phase 2 clinical trial design; the potential for final data not being consistent with or different than the interim data reported for any of our programs; the potential impact of Trump Administration policies and changes in law on our business; and those uncertainties and factors described under the heading “Risk Factors,” “Risk Factor Summary” and “Note about Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that the Company has filed or will file with the SEC, as well as discussions of potential risks, uncertainties, and other filings by the Company from time to time, as well as risk factors associated with companies that operate in the biopharma industry, including those associated with the uncertainties of drug development. All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company’s plan, objectives and goals and may not be appropriate for other purposes. The reader is cautioned not to place undue reliance on forward-looking statements. Industry Information This presentation also contains or references certain industry data that is based upon information from independent industry publications, market research, and surveys and other publicly available sources. Although the Company believes these sources to be generally reliable, such information is subject to interpretation and cannot be verified with complete certainty due to limits on the availability and reliability of data, the voluntary nature of the data gathering process and other inherent limitations and uncertainties. The Company has not independently verified any of the data from third party sources referred to in this presentation and accordingly, the Company makes no representation or warranty as to the origin, validity, accuracy, completeness, currency or reliability of the information in this presentation.
Page 3
3 © 2025 Spyre Therapeutics, Inc. All rights reserved. Anticipated 9 proof-of-concept readouts in 2026-27 Milestones expected as of the date of this presentation. 1Cash includes cash, cash equivalents, & marketable securities as of 3/31/25. UC=ulcerative colitis; RD=rheumatological disease; RA=rheumatoid arthritis; PsA=psoriatic arthritis; axSpA=axial spondyloarthritis; POC=proof of concept $565 million of cash as of March 31, 20251, with expected runway into 2H 2028 Trial Indication Program Target Phase 1 Phase 2 Phase 3 Anticipated Milestones UC SPY001 2026: Ph2 open-label POC 2027: Ph2 pbo-controlled dataSPY002 SPY003 SPY120 2027: Ph2 POCSPY130 SPY230 RA SPY072 2026: Ph2 POCPsA axSpA α4β7 TL1A IL-23 α4β7 + TL1A α4β7 + IL-23 TL1A + IL-23 TL1A
Page 4
4 © 2025 Spyre Therapeutics, Inc. All rights reserved. Engineering for new heights in the treatment of IBD & beyond Validated targets Half-life extension Fixed-dose combinations Concept image of drug delivery device shown for illustrative purposes only. Coformulations TL1A IL-23 α4β7 MOAs rationally chosen based on attractive risk-benefit profiles Engineered for prolonged activity to enable infrequent administration Rational combinations to address distinct disease drivers Potential best-in-class monotherapies & combinations in IBD Potential first-in-class anti-TL1A in rheumatologic conditions YTE
Page 5
5 © 2025 Spyre Therapeutics, Inc. All rights reserved. Our next-generation antibodies are engineered to match or exceed the potency of first-generation molecules SPY001 (α4β7) potency SPY002 (TL1A) potency SPY003 (IL-23) potency Data on file. Potency refers to in vitro potency: SPY001 assay reports inhibition of cells expressing a4b7 binding to MAdCAM-1. SPY002 assay reports inhibition of TL1A-induced apoptosis in TF-1 cells. SPY003 assay reports inhibition of cellular STAT3 signaling. Vedolizumab, tulisokibart, and risankizumab are synthesized comparator antibodies. 0.01 0.1 1 10 0 10 20 30 40 50 60 mAb Concentration (nM) %Inhibition 0.001 0.01 0.1 1 10 100 0 50 100 mAb Concentration (nM) % Inhibition 0.001 0.01 0.1 1 10 100 0 20 40 60 80 100 mAb Concentration (nM) Inhibition % Potential for comparable efficacy at similar or lower doses Potential upside: Improved efficacy with higher exposures Vedolizumab SPY001 Tulisokibart Risankizumab SPY002 SPY003 α4β7 TL1A IL-23
Page 6
6 © 2025 Spyre Therapeutics, Inc. All rights reserved. Each of our programs harness the body’s natural recycling mechanism for antibodies to prolong activity YTE modification YTE-modified mAbs are returned to circulation for continued activity mAb=monoclonal antibody; FcRn=neonatal Fc receptor; YTE=M252Y, S254T, and T256E amino acid substitution. Antibodies are subject to degradation when internalized YTE modification increases binding to FcRn when internalized FcRn binding promotes recycling of mAbs to circulation YTE FcRn YTE
Page 7
7 © 2025 Spyre Therapeutics, Inc. All rights reserved. YTE modification significantly extends half-life relative to first generation comparators … SPY001 human PK simulation SPY002 human PK simulation SPY003 NHP PK SPY001 PK simulation based on PK data as of 03/19/2025 cutoff., SPY002 PK simulation based on PK data from 5/31/2025 cutoff. Rosario, M, et. al. (2015); Danese, Silvio, et al. Official journal of the American College of Gastroenterology | ACG 119.10S (2024). Risankizumab is a synthesized comparator antibody in NHP study. Greater than 3x half-life vs. first-generation comparator molecules 0 14 28 42 56 70 84 98 1 10 100 1000 Days Serum Conc. (μg/mL) Vedolizumab SPY001 Afimkibart / Tulisokibart Risankizumab SPY002 SPY003
Page 8
8 © 2025 Spyre Therapeutics, Inc. All rights reserved. … supporting potential for quarterly or twice annual dosing across our portfolio SPY001 Target Profile SPY002 Target Profile SPY003 Target Profile Based on PK modeling for each program. Concept image of drug delivery device shown for illustrative purposes only. ≥ 180 mg/mL formulations 2-4 Chronic doses per year 2-4 Chronic doses per year 2-4 Chronic doses per year
Page 9
9 © 2025 Spyre Therapeutics, Inc. All rights reserved. Developing potential paradigm-changing combination therapies in IBD Inflammatory bowel disease Rational combinations targeting diverse disease drivers Potential Q3M-Q6M chronic dosing interval based on PK modeling. Concept image of drug delivery device shown for illustrative purposes only. Target Q3M-Q6M chronic dosing SPY120 SPY130 SPY230 α4β7 TL1A IL-23 α4β7 TL1A IL-23 IBD
Page 10
10 © 2025 Spyre Therapeutics, Inc. All rights reserved. Expanding into rheumatology with a distinct anti-TL1A program Rheumatology Potential first-in-class anti-TL1A Potential Q3M-Q6M chronic dosing interval based on PK modeling. SPY072 Rheumatoid arthritis Psoriatic arthritis Axial spondyloarthritis Target Q3M-Q6M dosing Target Q3M-Q6M dosing Target Q3M-Q6M dosing RA axSpA PsA
Page 11
11 © 2025 Spyre Therapeutics, Inc. All rights reserved. Transitioning to a mid-stage development company with two innovative Ph2 clinical trials 1Savings relative to separate Ph2 trials for each program (SKYLINE) or indication (SKYWAY) 6 AGENTS 1 INDICATION COST SAVINGS1 1 AGENT 3 INDICATIONS COST SAVINGS1 40% 35% PsA axSpA RA SPY072 high SPY072 low Placebo SPY072 Placebo SPY072 Placebo UC Placebo SPY001 SPY002 SPY003 SPY120 SPY130 SPY230 MonosCombos Ph2 platform trial evaluating SPY001, SPY002, SPY003 and pairwise combinations in ulcerative colitis Ph2 basket trial evaluating SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis Initiated May 2025 Initiation anticipated 3Q 2025
Page 12
12 © 2025 Spyre Therapeutics, Inc. All rights reserved. Potential additive paths to significant value creation in 2026-27 Milestones expected as of the date of this presentation. 1Precedent valuations provided for illustrative purposes only and may not be indicative of potential Spyre valuation; 2Vertex valuation following proof-of-concept for first Phase 2 combination study of VX-770 and VX-809. OL=open label; Check marks refer to interim Ph1 results. 2H 2025 mid- 2025 2026 2027 Trial Phase 1s Programs SPY001 SPY002 SPY072 SPY003 SPY001 SPY002 SPY003 SPY072 SPY120 SPY130 SPY230 Readout Interim safety, PK, PD HVs Monotherapy OL POC UC Anti-TL1A POC RA, PsA, axSpA Combination POC UC Analog type Validated MOA, improved convenience First-in-class MOA in $30B+ market Paradigm-changing combinations Precedent1 $3B+ acquisition $10B+ acquisition $10B+ post-POC2
Page 13
Inflammatory bowel disease Potential best-in-class monotherapies and combinations
Page 14
14 © 2025 Spyre Therapeutics, Inc. All rights reserved. Substantial unmet need remains for the millions of individuals living with IBD 1Lewis, James D., et al. Gastroenterology (2023). Estimate includes patients identified with indeterminate IBD. Clinical remission rates from product labels. 0 20 40 60 80 100 • ~2.4M individuals in the U.S. are diagnosed with IBD (~1.3M UC and ~1.0M CD)1 • Substantial unmet need remains due to: – Minority remission rates and lack of durability with existing therapies – Side effects and safety concerns associated with certain treatments – Poor adherence to frequent and/or inconvenient dosing regimens Efficacy ceiling of ~25% UC placebo-adjusted clinical remission rates by MOA (Induction) Anti-TNF JAK inhibitorS1P inhibitorAnti-integrin Anti-IL-12/23 / Anti-IL-23
Page 15
15 © 2025 Spyre Therapeutics, Inc. All rights reserved. JNJ’s VEGA study demonstrated the power of combination therapy to break the efficacy ceiling in IBD VEGA combination study • Ulcerative colitis Feagan, B. G. et al. Lancet Gastroenterol. Hepatol. 8, 307–320 (2023). 25% 24% 25% 22% Anti-TNF (Golimumab) Anti-IL-23 (Guselkumab) Combination 47% Δ+22% ~Additive absolute W12 mMS clinical remission rates
Page 16
16 © 2025 Spyre Therapeutics, Inc. All rights reserved. Replacing TNF with α4β7 or TL1A may yield combinations with improved safety and efficacy α4β7 was superior to TNF in H2H UC study TL1A exceeds TNF on cross-trial comparison Product labels, Sands BE. et al. N Engl J Med. 2019; Roivant corporate presentation January 2023; Sands, Bruce E., et al. New England Journal of Medicine 391.12 (2024); Teva corporate presentation February 2025. Established α4β7 long-term safety profile and gut-restrictive MOA TL1A safety is encouraging to date 23 31 0 10 20 30 40 adalimumab vedolizumab Clinical remission – week 52 (VARSITY) Δ +8% 11 20 25 27 0 10 20 30 40 Afimkibart Tulisokibart DuvakitugGolimumab Pbo-adjusted clinical remission - induction Δ +14% TNF TL1A TNF α4β7
Page 17
17 © 2025 Spyre Therapeutics, Inc. All rights reserved. Spyre MOAs address the diverse pathophysiology of IBD by targeting distinct pathways Blockade of α4β7 prevents circulating immune cells from entering inflamed gut tissues Neutralization of TL1A suppresses inflammation and reduces fibrosis by inhibiting fibroblast activation Neutralization of IL-23 inhibits cascade of various proinflammatory cytokines Created with BioRender.com; Neurath, Markus F. Nature Reviews Gastroenterology & Hepatology 14.5 (2017): 269-278; Solitano, Virginia, et al. Med (2024). anti-α4β7 anti-TL1A anti-IL-23
Page 18
18 © 2025 Spyre Therapeutics, Inc. All rights reserved. Spyre’s combinations demonstrate additive-to-superior efficacy in mouse TNBS colitis model α4β7 + TL1A α4β7 + IL-23 TL1A + IL-23 Data on file. Preclinical models utilized surrogate antibodies. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 vs. vehicle (2-way ANOVA with Dunnett’s correction). N=8 per group. TNBS=trinitrobenzene sulfonic acid -1 0 1 2 3 4 5 6 0 2 4 6 8 10 12 Days DAI score **** **** ***** **** **** **** **** **** ***** Healthy Vehicle Control anti-β7 anti-TL1A anti-β7 + anti-TL1A -1 0 1 2 3 4 5 6 0 2 4 6 8 10 12 Days Healthy Vehicle Control anti-TL1A anti-IL23 anti-TL1A + anti-IL23 **** **** ******* ********** ************ **** ******** * Disease improvement -1 0 1 2 3 4 5 6 0 2 4 6 8 10 12 Days **** ******** ****** ******** **** **** **** ****** Healthy Vehicle control anti-β7 anti-IL-23 anti-β7 + anti-IL-23
Page 19
19 © 2025 Spyre Therapeutics, Inc. All rights reserved. Spyre’s portfolio uniquely enables product profiles with potential superior efficacy and convenience Positioning of Spyre programs is illustrative and based on Phase 1 results for SPY001 and SPY002 only and illustrates what we believe we can potentially achieve. Placebo-adjusted clinical remission data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. 0 1 2 3 4 5 6 20 40 60 80 Maintenance dosing interval (months) Pbo-adjusted clinical remission (%) Potential for Q3M & Q6M dosing profiles ILLUSTRATIVE SPY001 SPY002 SPY003 Potential to break the efficacy ceiling with combinationsSPY120 SPY130 SPY230 Potential for best-in-class efficacy with higher exposuresStandard of care IBD biologics
Page 20
20 © 2025 Spyre Therapeutics, Inc. All rights reserved. Coformulations are more likely to achieve the optimal target profile compared to bispecifics Sources: Zheng, Songmao, et al. Mabs. (2020); Kroenke, Mark A., et al. Frontiers in Immunology 12 (2021); clinicaltrials.gov; bsAb=bispecific antibody 1:1 Fixed antibody ratios limits dose flexibility/optimization Reduced avidity reduces target engagement Immune complex formation & immunogenicity to unique constructs increases clearance & reduces target engagement Potential challenges unique to bispecifics Potential impact on product profile Examples Increased total dosage to saturate the more abundant target Increased total dosage to achieve full target engagement Increased and/or more frequent dosing Decreased durability Lack of drug-like properties JNJ-8104 (TNF/IL-17) ABT-122 (TNF/IL-17) AMG-966 (TL1A/TNF) PF-07261271 (TL1A/p40) JNJ-8104 (TNF/IL-17) MEDI-7352 (TNF/NGF) >20-fold decrease in potency observed with JNJ-8104 bsAb vs. parental mAb co-administration 1:1 2:2
Page 21
21 © 2025 Spyre Therapeutics, Inc. All rights reserved. Co-administration of mAbs can reduce immunogenicity whereas bispecific formats can increase immunogenicity ADA rates for bsAbs vs. coformulations Case studies Clin Pharmacol Ther. 2017;101(S1):S81; J. of Clin Pharmacol. 2019; 59(7): 968-978; J. of Clin Pharmacol. 2018; 58(6): 803-813; Front Immunol. 2021 Dec 14:12:782788; Shao et al. Clin Pharmacol Ther. 2024 Jun;115(6):1418-1427. doi: 10.1002/cpt.3235. OA=osteoarthritis; UC=ulcerative colitis; HV=healthy volunteers. Asset Target Immunogenicity Population Structure golimumab + guselkumab (JNJ-4804) TNFα + IL-23 UC Separate human IgG1 mAbs JNJ-3539 TNFα / IL-17 HVs IgG-fynomer (2x2) JNJ-8104 TNFα / IL-17 HVs Duobody (1x1) ABT-122 TNFα / IL-17 HVs Dual variable domain (2x2) AMG-966 TNFα / TL1A HVs Four unique heavy and light chain pairs (1x1) MEDI-7352 TNFα / NGF OA IgG-scFv (2x2) RO7837195 (PF-07261271) TL1A / p40 HVs CrossmAb (1x1) 6% 93% 100% 99% 98% 72% 100% CombobsAbs DISCONTINUED DISCONTINUED DISCONTINUED DISCONTINUED DISCONTINUED PHASE 2 … We demonstrate here that AMG966 forms large immune complexes ... which drive an antibody response and resulted in loss of exposures … … Combination therapy appeared to decrease the incidence of antibodies to golimumab … PHASE 2 TL1A trimer TNF trimer AMG-966 IL-23 dimer TNF trimer guselkumab golimumab AMG-966 ADAs Time Time Exposure Exposure Golimumab Guselkumab No impact on drug exposure Loss of drug exposure AMG-966 bispecific JNJ-4804 coformulation
Page 22
22 © 2025 Spyre Therapeutics, Inc. All rights reserved. SKYLINE-UC: Phase 2 platform study evaluating three monotherapies and three combinations in UC mMS=modified mayo score; RHI=Robarts Histopathology Index; HEMI=Histo-Endoscopic Mucosal Improvement; P=primary endpoint; S=secondary endpoint Initiation of each cohort subject to regulatory clearance. Part A: Open-label monotherapy evaluation (N=~100) SPY001 (α4β7) SPY002 (TL1A) SPY003 (IL-23) SPY120 (α4β7+TL1A) SPY130 (α4β7+IL-23) SPY230 (TL1A+IL-23) Placebo OBJECTIVES KEY ENDPOINTS W12 W48 Seamless enrollment after Part A Monotherapy POC Change in RHI at W12 Clinical remission at W12 Endoscopic improvement at W12 Change in mMS at W12 P S Monotherapy dose optimization Combination POC Contribution of components S Clinical remission at W12 Endoscopic improvement at W12 Clinical response at W12 Histological improvement at W12 HEMI at W12 Clinical remission at W48 P S S S S S S SPY001 (α4β7) SPY002 (TL1A) SPY003 (IL-23) INDUCTION MAINTENANCE W12 W48 Sequential activation after Ph1 P Part B: PBO-controlled factorial combination evaluation (N=~550) UC mMS 5-9 UC mMS 5-9 P INDUCTION MAINTENANCE
Page 23
23 © 2025 Spyre Therapeutics, Inc. All rights reserved. Capital-efficient trial that is designed to be attractive to patients and investigators 40% PATIENT CENTRIC STREAMLINED UNIFIED DOSING INDUCTION MAINTENANCEPART A PART B 6 actives vs. 1 placebo MonosCombosPlacebo Open-label Cost savings and reduced sample size compared to individual Ph2 studies for each program CAPTIAL EFFICIENT
Page 24
24 © 2025 Spyre Therapeutics, Inc. All rights reserved. SKYLINE-UC: First patients in screening and on-track for expected 6 POC readouts through 2027 Milestones expected as of the date of this presentation. Phase 1 SPY003 Ph1 Phase 2 platform study Ph2 Initiation Part A monotherapy results SPY001 (α4β7) open-label POC SPY002 (TL1A) open-label POC SPY003 (IL-23) open-label POC Part B monotherapy results SPY001 (α4β7) pbo-controlled data SPY002 (TL1A) pbo-controlled data SPY003 (IL-23) pbo-controlled data Part B combination results SPY120 (α4β7+TL1A) POC SPY130 (α4β7+IL-23) POC SPY230 (TL1A+IL-23) POC Phase 2 basket study Ph2 Initiation Ph2 results SPY072 (TL1A) RA POC SPY072 (TL1A) PsA POC SPY072 (TL1A) axSpA POC 2026 20272H 2025 6 POC readouts 3 POC readouts
Page 25
Rheumatology Potential first-in-class anti-TL1A in RA, PsA, and axSpA
Page 26
26 © 2025 Spyre Therapeutics, Inc. All rights reserved. Substantial unmet need remains for the millions of individuals living with RA, PsA, and axSpA 1Hunter, Theresa M., et al. Rheumatol Int (2017); 2Ogdie, Alexis, et al. Rheumatol Ther (2021). Efficacy rates by MOA from product labels. Note: 3Week 24 data when available, otherwise data is Week 12 or 16; 4Includes IL-12/23 and IL-23 0 20 40 60 80 100 TNF JAK IL-6 CD20 CD80/86 • >3M individuals in the U.S. diagnosed with RA (>1.5M1), PsA (~1M2), and axSpA (~1M2) • Substantial unmet need remains due to: – Minority remission rates, inability to control multiple aspects of disease, and lack of durability with existing therapies – Limited MOAs to cycle through following incomplete responses – Poor adherence to frequent and/or inconvenient dosing regimens Placebo-adjusted efficacy rates by MOA (W243) TNF JAK IL-17 TNF JAK IL-17 IL-234 RA (ACR50) axSpA (ASAS40)PsA (ACR50)
Page 27
27 © 2025 Spyre Therapeutics, Inc. All rights reserved. TL1A has strong biological rationale in rheumatology, sharing TL1A-associated cellular pathways with IBD TL1A exacerbates inflammation and fibrosis TL1A has been implicated in a wide range of human diseases driven by cellular pathways Figure created with BioRender.com. 1 Logos indicate planned or active clinical POC studies. Hisamoto, T. et al. Int. J. Mol. Sci. 24, 1813 (2023); Herro, R. et al. J. Immunol. 205(9), 2414-2422 (2020); Ma, C. et al. Int. Immunopharm. 137, 112360 (2024); Richard, A. et al. JLB 3(98), 333-345 (2015); Song, Y. et al. Arthritis Research & Therapy 22, 106 (2020); Xu, W. et al. Frontiers in Immunology 13, 891328 (2022). Increasing overlap with clinically validated biology POC studies1 TH1 | TH17 | TH9 Fibroblasts FLS | osteoclasts NK | TH2 | ILCs Ulcerative colitis (UC) • Crohn’s disease (CD) • • Rheumatoid arthritis (RA) • • Psoriatic arthritis (PsA) • Axial spondyloarthritis (axSpA) • Psoriasis (PsO) • Hidradenitis suppurativa (HS) • • Primary biliary cholangitis (PBC) • • Pulmonary sarcoidosis • Interstitial lung disease (SSc-ILD) • Metabolic steatohepatitis (MASH) • Atopic dermatitis (AD) • Asthma •
Page 28
28 © 2025 Spyre Therapeutics, Inc. All rights reserved. TL1A is upregulated in RA, PsA, and axSpA relative to healthy controls Rheumatoid arthritis Psoriatic arthritis Axial spondyloarthritis Spyre analysis of RA-MAP, Li, Sifang, et al. BMC Musculoskeletal Disorders 25.1 (2024), and Johnsson, Hanna, et al. Arthritis Research & Therapy. ** P≤0.01, *** P ≤0.001, **** P ≤0.0001. Unpaired tailed t-test used for RA and axSpA analysis, One-way ANOVA used in PsA. RA=rheumatoid arthritis; PsA=psoriatic arthritis; axSpA=axial spondyloarthritis; HC=healthy controls. Source Whole blood Sequencing Microarray Sample size N=192 RA, 30 HC Skin biopsy Bulk RNA seq N=9 per cohort Whole blood Microarray N=52 axSpA, 20 HC Healthy Control PsA Uninvolved PsA Lesion -50 0 50 100 150 200TNFSF15 Counts ✱✱ ✱✱ Healthy Control axSpA 0 200 400 600 800TNFSF15 Counts ✱✱✱ Healthy Control Rheumatoid arthritis -2000 0 2000 4000 6000 8000 TNFSF15 Counts ✱✱✱✱
Page 29
29 © 2025 Spyre Therapeutics, Inc. All rights reserved. Spyre anti-TL1A antibody meets or exceeds the efficacy of etanercept (anti-TNF) in rat models of arthritis Superior efficacy in semi-preventative model Comparable efficacy in therapeutic model * P< 0.0001 vs. isotype control; 2-way ANOVA using Dunnett's correction for multiple comparisons. Data on file. 5 10 15 20 25 0 2 4 6 8 Day Arthritis score Healthy Vehicle Isotype control anti-TNF anti-TL1A 5 10 15 20 25 0 2 4 6 8 Day Arthritis score Healthy Vehicle anti-TL1A anti-TNF Isotype control * * * * * Treatment periodTreatment periodCollagen Collagen Disease improvement Disease improvement
Page 30
30 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY072 is a potential first-in-class therapy for rheumatologic conditions with quarterly or twice-annual dosing Positioning of Spyre programs is illustrative and based on Phase 1 interim results. Placebo-adjusted clinical data are derived from different clinical trials conducted at different times, with differences in trial design and patient populations. As a result, cross-trial comparisons cannot be made, and no head-to-head clinical trials have been conducted. 0 1 2 3 4 5 6 10 20 30 40 50 60 Dosing interval (months) Pbo-adjusted ACR20 / ASAS20 (%) Potential for novel MOA with comparable-to-better efficacy and improved SC dosing frequency (Q3M-Q6M)PsA RA axSpA Today’s SOC ILLUSTRATIVE
Page 31
31 © 2025 Spyre Therapeutics, Inc. All rights reserved. SKYWAY-RD: Phase 2 basket study evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA RF=rheumatoid factor; ACPA= Anti-citrullinated protein antibodies; cs/b/tsDMARD=conventional synthetic, biologic, or targeted synthetic disease modifying antirheumatic drugs; BASDAI=Bath Ankylosing Spondylitis Disease Activity Index; P=primary endpoint; S=secondary endpoint; E=exploratory endpoint. Pending regulatory feedback. Sub-study A: SPY072 in moderate-to-severely active rheumatoid arthritis (RA) SPY072 Dose A SPY072 Dose B Placebo DOUBLE-BLIND OPEN-LABEL FOLLOW UP RA N=120 KEY INCLUSION KEY ENDPOINTS W12 W36 1:1:1 Swollen joint count ≥ 4 Tender joint count ≥ 4 RF+, ACPA+, or bony erosions IR to cs/b/tsDMARDs Change in DAS28-CRP at W12 Proportion ACR20 at W12 ACR50/70 at W12 P S Sub-study B: SPY072 in moderate-to-severely active psoriatic arthritis (PsA) SPY072 Dose A Placebo PsA N=90 W16 W40 2:1 Tender joint count ≥ 3/68 Swollen joint count ≥ 3/66 Active PsO lesion or history IR to NSAIDs or cs/b/tsDMARDs Proportion ACR20 at W16 Change in DAPSA at W16 ACR50/70 at W16 P S Sub-study C: SPY072 in moderate-to-severely active axial spondyloarthritis (axSpA) SPY072 Dose A Placebo axSpA N=75 W16 W40 2:1 Radiographic / non-radiographic BASDAI ≥ 4 & back pain ≥ 4 IR to NSAIDs or b/tsDMARDs Change in ASDAS at W16 Proportion ASAS40 at W16 P S E E
Page 32
32 © 2025 Spyre Therapeutics, Inc. All rights reserved. Operationally-efficient design with shared sites and specialty 1Based on comparative CRO quotes. 35% SHARED SITES SHARED SPECIALTY Cost savings compared to individual Ph2 studies for each indication1 CAPITAL EFFICIENT Rheumatologist PsA patients axSpA patients RA patients Increased investigator productivity 50 5030 20 Separate studies SKYWAY-RD PsA RA axSpA 100 50% Reduced total site requirement
Page 33
33 © 2025 Spyre Therapeutics, Inc. All rights reserved. SKYWAY-RD: 3 POC readouts expected through 2026 Milestones expected as of the date of this presentation and pending regulatory feedback. Phase 1 SPY003 Ph1 Phase 2 platform study Ph2 Initiation Part A monotherapy results SPY001 (α4β7) open-label POC SPY002 (TL1A) open-label POC SPY003 (IL-23) open-label POC Part B monotherapy results SPY001 (α4β7) pbo-controlled data SPY002 (TL1A) pbo-controlled data SPY003 (IL-23) pbo-controlled data Part B combination results SPY120 (α4β7+TL1A) POC SPY130 (α4β7+IL-23) POC SPY230 (TL1A+IL-23) POC Phase 2 basket study Ph2 Initiation Ph2 results SPY072 (TL1A) RA POC SPY072 (TL1A) PsA POC SPY072 (TL1A) axSpA POC 2026 20272H 2025 6 POC readouts 3 POC readouts
Page 34
Corporate Leadership and cash runway
Page 35
35 © 2025 Spyre Therapeutics, Inc. All rights reserved. Leadership Scott Burrows Chief Financial Officer Brian Connolly Chief Technical Officer Joshua Friedman SVP, Clinical Development Janet Gunzner-Toste SVP, Operations MiRa Huyghe SVP, Development Operations Heidy King-Jones Chief Legal Officer and Corporate Secretary Justin LaFountaine SVP, Corporate Development Deanna Nguyen SVP, Clinical Development Andrew Spencer SVP, Preclinical Research and Development Cameron Turtle Chief Executive Officer Paul Fehlner SVP, Chief Intellectual Property Counsel Melissa Cooper SVP, People Sheldon Sloan Chief Medical Officer Cristina Damatarca SVP, Drug Safety & Pharmacovigilance
Page 36
36 © 2025 Spyre Therapeutics, Inc. All rights reserved. Board of Directors Mark McKenna Peter Harwin Michael Henderson Tomas Kiselak Laurie Stelzer Cameron Turtle Jeffrey Albers Sandra Milligan
Page 37
37 © 2025 Spyre Therapeutics, Inc. All rights reserved. Anticipated 9 proof-of-concept readouts in 2026-27 for the treatment of IBD & beyond Milestones expected as of the date of this presentation and pending regulatory feedback. Phase 1 SPY003 Ph1 Phase 2 platform study Ph2 Initiation Part A monotherapy results SPY001 (α4β7) open-label POC SPY002 (TL1A) open-label POC SPY003 (IL-23) open-label POC Part B monotherapy results SPY001 (α4β7) pbo-controlled data SPY002 (TL1A) pbo-controlled data SPY003 (IL-23) pbo-controlled data Part B combination results SPY120 (α4β7+TL1A) POC SPY130 (α4β7+IL-23) POC SPY230 (TL1A+IL-23) POC Phase 2 basket study Ph2 Initiation Ph2 results SPY072 (TL1A) RA POC SPY072 (TL1A) PsA POC SPY072 (TL1A) axSpA POC 6 POC readouts 3 POC readouts 2026 20272H 2025
Page 38
38 © 2025 Spyre Therapeutics, Inc. All rights reserved. Cash and shares outstanding 1Cash includes cash, cash equivalents, & marketable securities as of 3/31/25; 2Shares outstanding on a pro forma and as-converted basis as of 3/31/25, which (i) gives effect to the full conversion of the Company’s preferred stock, and (ii) disregards beneficial ownership limitations that may limit the ability of certain holders of preferred stock to convert into common stock. Common stock Common stock equivalents $565M cash as of March 31, 20251 Expected runway into 2H 2028 Number of shares (M) Shares outstanding • Series A preferred stock • Series B preferred stock Total outstanding 60.3 13.8 0.7 74.8Common stock and common stock equivalents2
Page 39
Engineering for new heights in the treatment of IBD and beyond THANK YOU
Page 40
40 © 2025 Spyre Therapeutics, Inc. All rights reserved. Appendix: SPY001 (α4β7) interim Ph1 results Interim data as of 3/19/25 cutoff. SPY001 Well tolerated with a favorable safety profile PK supports quarterly or less frequent dosing Rapid & sustained target engagement No apparent impact of ADAs on PK/PD
Page 41
41 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY001 potency & selectivity match vedolizumab in vitro SPY001 & vedolizumab epitope Potent and selective inhibition of cellular adhesion Data on file. α4 Subunit β7 Subunit SPY001 and vedolizumab bind the same epitopeAntibody α4β71 α4β1 αEβ7 SPY001 KD <1 nM NB2 NB2 Vedolizumab KD <1 nM NB2 NB2 1Dissociation constant (KD) measured by surface plasmon resonance (SPR); 2NB = no binding by a particular antibody to a test molecule 0.001 0.01 0.1 1 10 100 -10 0 10 20 30 40 50 60 70 mAb Concentration (nM) %Inhibition of Total Adhesion (Integrin-mediated Adhesion by VCAM-1) Vedolizumab SPY001 Natalizumab 0.01 0.1 1 10 0 10 20 30 40 50 60 70 mAb Concentration (nM) %Inhibition of Total Adhesion (Integrin-mediated Adhesion by MAdCAM-1) Vedolizumab (IC50 = 83 pM) SPY001 (IC50 = 86 pM) SPY001 and vedolizumab potently inhibit MAdCAM-1-mediated (gut) cellular adhesion No inhibition of unwanted VCAM-1- mediated (CNS) cellular adhesion
Page 42
42 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY001 was well-tolerated with a favorable safety profile TEAE=treatment-emergent adverse events. TESAE=treatment-emergent serious adverse events. 1Injection site discomfort starting 6 hours after 4 SC injections and resolved 2 hours later without intervention. 2Dyspepsia; The most common TEAEs were headache and nasopharyngitis Interim data as of 3/19/25 cutoff. N (%) 100 mg 300 mg 600 mg 1000 mg 1000 mg SAD Pooled 300 mg 600 mg MAD Pooled N= 8 8 8 8 8 40 8 8 16 At least one TEAE 1 (13%) 5 (63%) 4 (50%) 3 (38%) 2 (25%) 15 (38%) 4 (50%) 3 (38%) 7 (44%) At least one TESAE 0 0 0 0 0 0 0 0 0 At least one Drug-related AE 0 0 0 1 (13%)1 0 1 (3%) 0 0 0 At least one ≥Grade 2 TEAE 0 0 0 1 (13%)2 0 1 (3%) 0 0 0
Page 43
43 © 2025 Spyre Therapeutics, Inc. All rights reserved. Extended data demonstrated ~80-day half-life, more than 3- fold that of the published vedo half-life1 Half-lifeSPY001 simulated concentration-time profile Vedolizumab PopPK simulation based on published PK parameters of vedolizumab, Rosario, M, et. al. (2015), SPY001 PopPK simulation based on PK data as of 03/19/2025 cutoff. ~80 days ~25 days >3-fold SPY001 VEDO Serum Conc. (µg/mL) SPY001 300mg SC Vedolizumab 300mg SC Median +/- IQR
Page 44
44 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY001 exhibits dose-proportional pharmacokinetics SAD mean PK profiles MAD mean PK profiles Interim data as of 3/19/25 cutoff.
Page 45
45 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY001 saturated α4β7 receptors through 32 weeks of follow-up at clinically-relevant exposures SAD & MAD mean PD profiles PK-PD relationship Data shown are Mean +/- SD for each cohort at each visit; pooled placebo as of 03/19/2025 data cutoff. (n): SAD Placebo (4-10), SPY001 100 mg SC (6), SPY001 300 mg SC (5-6), SPY001 600 mg SC (5-6), SPY001 1000 mg SC (6), and SPY001 1000 mg IV (5-6); MAD Placebo (2-4), SPY001 300 x 2 mg SC (6), and SPY001 600 x2 mg IV (6). Data have been slightly offset for visualization. Interim data as of 3/19/25 cutoff. Threshold for target saturation Range of expected clinical exposures Time (weeks)
Page 46
46 © 2025 Spyre Therapeutics, Inc. All rights reserved. Modeled SPY001 induction exposures exceeded those of vedolizumab with all patients anticipated in quartile 4 Phase 2 Induction human PK simulations 1Casteele, N. V. et al. Aliment. Pharmacol. Ther. 56, 463–476 (2022); 2Vedolizumab FDA Clinical Pharmacology Review; PK simulation for comparator molecules based on published clinical data.. Simulations based on Interim data as of 3/19/25 cutoff. 37% 31% 20% 12% Quartile 4 (41-100 µg/mL) Quartile 3 (32-41 µg/mL) Quartile 2 (25-32 µg/mL) Quartile 1 (2-25 µg/mL) +25% Vedolizumab Week 14 Deep Remission Rates in UC (%)1 By Week 6 trough concentration quartile Serum Conc. (µg/mL) Targeting all patients with W6 concentration in Quartile 4 SPY001 Vedolizumab 0 50 100 % patients in Q4Vedo SPY001 ~25% ~100% FDA pharmacology review recommended testing higher vedo doses post-marketing with the aim to improve induction efficacy2 Median +/- IQR Vedo W6 Quartile 4 Potential upside: Greater remission w/ higher exposure
Page 47
47 © 2025 Spyre Therapeutics, Inc. All rights reserved. Interim PK supports quarterly or twice annual dosing Maintenance human PK simulations Data on file, simulations represent median +/- interquartile range; SPY001 simulation based on PK data as of 03/19/2025 cutoff. Serum Conc. (µg/mL) SPY001 Q3M SC SPY001 Q6M SC Vedolizumab Q2W SC MaintenanceInduction 2-4x SC maintenance injections per year
Page 48
48 © 2025 Spyre Therapeutics, Inc. All rights reserved. Appendix: SPY002 and SPY072 (TL1A) interim Ph1 results Interim data as of May 30, 2025 cutoff SPY072 SPY002 Well tolerated with a favorable safety profile PK supports quarterly or less frequent dosing Rapid & sustained target engagement No apparent impact of ADAs on PK/PD
Page 49
49 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY002 and SPY072 each target distinct epitopes and exhibit unique binding properties Single TL1A subunit epitope Superior or comparable potency in multiple assays Data on file. Duvakitug not benchmarked in IFNγ secretion assay; Duvakitug, RO7790121, and tulisokibart are synthesized comparator antibodies. Superior or comparable inhibition of TF-1 apoptosis Superior or comparable inhibition of IFNγ secretionSPY002 and SPY072 each target a distinct epitope on a single TL1A monomer Tulisokibart (MK-7240) RO7790121 (RVT-3101) Duvakitug (TEV-48574) • Epitope locations were resolved by CryoEM • Illustrative locations are overlayed with the crystal structure of trimeric TL1A 0.01 0.1 1 10 100 0 20 40 60 80 100 mAb Concentration (nM) Inhibition % mAb Concentration (ng/mL) Inhibition% 0.1 1 10 100 1000 10000 100000 0 20 40 60 80 100 Tulisokibart RO7790121 Duvakitug SPY002 & SPY072
Page 50
50 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY002 and SPY072 were each well tolerated with a favorable safety profile (pooled, blinded data) Interim analysis as of May 30, 2025 data cutoff. 1Headache and migraine.2Chest tightness; Gastroenteritis, rash, and abdominal pain in one subject. 3Chest tightness. SPY002 safety profile SPY072 safety profile N (%) 100 mg 300 mg 300 mg 1000 mg 1500 mg SAD Pooled N= 8 8 8 8 8 40 At least one TEAE 3 (38%) 2 (25%) 3 (38%) 3 (38%) 0 11 (28%) At least one TESAE 0 0 0 0 0 0 At least one Treatment- related AE 2 (25%)1 0 0 0 0 2 (5%) At least one Grade 3/4 TEAE 0 0 0 0 0 0 100 mg 300 mg 300 mg 1000 mg 1500 mg SAD Pooled 8 8 8 8 8 40 2 (25%) 5 (63%) 5 (63%) 2 (25%) 1 (13%) 14 (35%) 0 0 0 0 0 0 0 2 (25%)2 0 1 (13%)3 0 3 (8%) 0 0 0 0 0 0
Page 51
51 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY002 and SPY072 demonstrated prolonged and dose proportional PK SPY002 mean PK profiles SPY072 mean PK profiles Interim analysis as of May 30, 2025 data cutoff. Waiting for comparable follow-up to accurately estimate half-life ~75-day t1/2 Pending t1/2
Page 52
52 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY072 showed comparable PK to SPY002 at clinically relevant doses through available follow up SPY002 & SPY072 mean PK profiles (IV) SPY002 & SPY072 mean PK profiles (SC) Interim analysis as of May 30, 2025 data cutoff. Remove 1500 ~75-day t1/2 Pending t1/2SPY072 SPY002 1000 mg IV (N=6) 300 mg IV (N=6) 1000 mg IV (N=6) 300 mg IV (N=6) ~75-day t1/2 Pending t1/2SPY072 SPY002 300 mg SC (N=6) 100 mg SC (N=6) 300 mg SC (N=6) 100 mg SC (N=6)
Page 53
53 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY002 and SPY072 suppressed free TL1A through 20- weeks of follow-up at the lowest dose tested SPY002 median free sTL1A PD profiles SPY072 median free sTL1A PD profiles Interim analysis as of May 30, 2025 data cutoff. Median values below LLOQ of 8pg/mL plotted as one-half of LLOQ per convention.
Page 54
54 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY002 and SPY072 increased total TL1A in a durable and dose-dependent manner SPY002 mean total sTL1A PD profiles SPY072 mean total sTL1A PD profiles Interim analysis as of May 30, 2025 data cutoff.
Page 55
55 © 2025 Spyre Therapeutics, Inc. All rights reserved. Interim PK supports quarterly or twice annual dosing Afimkibart Ph2 UC results SPY002 simulated concentration-time profile SPY002 simulations based on interim analysis as of May 30, 2025 data cutoff. Afimkibart simulations based on Danese, Silvio, et al. Official journal of the American College of Gastroenterology | ACG 119.10S (2024). mMS = Modified Mayo Score. SPY002 Q3M SC SPY002 Q6M SC Afimkibart QM SC 30% 31% 38% 39% 29% 36% 0 10 20 30 40 50 Clinical remission by mMS % Week 14 Week 56 50 mg Q4W 150 mg Q4W 450 mg Q4W Induction Maintenance 2-4x SC maintenance injections per year SPY002 Q3M SPY002 Q6M Afimkibart simulated 450mg Ctrough Afimkibart simulated 150mg Ctrough Afimkibart simulated 50mg Ctrough N=46 N=29 N=28 N=42 N=26 N=28
Page 56
56 © 2025 Spyre Therapeutics, Inc. All rights reserved. Appendix: SPY003 (IL-23) preclinical data SPY003 Similar epitope as risankizumab Exhibits >3x the half-life of risankizumab in NHPs Phase 1 study initiated in 1Q 2025 Expected 2025 Ph1 readout2H
Page 57
57 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY003 targets a similar epitope as risankizumab with comparable potency in vitro Similar epitope to risankizumab Comparable potency in multiple assays Data on file. Risankizumab is a synthesized comparator antibody. 0.01 0.1 1 10 100 1000 0 50 100 mAb Concentration (nM) % Inhibition 0.001 0.01 0.1 1 10 100 0 50 100 mAb Concentration (nM) % Inhibition SPY003 epitope Risankizumab epitope SPY003 and risankizumab potently inhibit pSTAT signaling SPY003 and risankizumab potently inhibit IL-17 release SPY003 and risankizumab bind the same p19 subunit of IL-23
Page 58
58 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY003 exhibits >3x the half-life of risankizumab in NHPs Half-lifeNHP PK profiles of SPY003 and risankizumab Data on file. Group size was n = 4 in the NHP studies with n = 4 and n = 3 at the final timepoint for half-life determination for SPY003 and risankizumab, respectively. Risankizumab is a synthesized comparator antibody. ~30 days ~9 days SPY003 Risankizumab ~3-fold vs. risankizumab 0 14 28 42 56 70 84 98 1 10 100 1000 Days Serum Conc. (μg/mL)
Page 59
59 © 2025 Spyre Therapeutics, Inc. All rights reserved. SPY003 Phase 1 initiated in 1Q 2025 Expected Ph1 study design Phase 1 milestones SAD 1 SAD 2 SAD 3 SAD 4 MD 1 Single-ascending and multiple dose (MD) cohorts • Healthy volunteers • n=8/cohort (3:1 randomization) Phase 1 initiation in 1Q 2025 Interim FIH data expected 2H 2025 Safety and tolerability Pharmacokinetics Immunogenicity
Page 60
60 © 2025 Spyre Therapeutics, Inc. All rights reserved. Phase 1 interim PK to confirm the potential of Q3M-Q6M maintenance dosing, as predicted by NHP data SPY003 human half-life targets Human PK simulations 1Human YTE mAb half-life is on average 3.1x of NHP half-life; Haraya, Kenta, and Tatsuhiko Tachibana. BioDrugs (2023); 2Skyrizi BLA 3Spyre preclinical studies; risankizumab is a synthesized comparator antibody. 30 28 9 Humans1 NHPs Humans2 NHPs3 Q6M based on PK modeling Q3M based on PK modelingHalf-life (days) SPY003RISA ~45 ~60 Q8W OBI Serum Conc. (µg/mL) SPY003 Risankizumab